Study of the SERAPHIN in Patients With Symptomatic Pulmonary Arterial Hypertension

Gender Preference	None
Age Group	18 - 99 years
Research Start Date	July 1, 2008
Research End Date	September 27, 2013
Principal Investigator	Sif Hansdottir, MD
Description	Long-term Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension (SERAPHIN OL) The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH. This study is closed to enrollment and in the follow-up phases. Please refer to www.clinicaltrials.gov identifier NCT00667823 for more information
Contact Info	Pulmonary Hypertension Study Page Scovel, RN phone: 319-356-1028 fax: 319-356-7087 email: page-scovel@uiowa.edu
Keywords	span itemProp='description'>Heart ; High blood pressure in lungs ; PAH ; PH ; Pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension ;

Contact